1. Home
  2. FOXX vs HOTH Comparison

FOXX vs HOTH Comparison

Compare FOXX & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foxx Development Holdings Inc. Common Stock

FOXX

Foxx Development Holdings Inc. Common Stock

HOLD

Current Price

$4.57

Market Cap

16.9M

Sector

N/A

ML Signal

HOLD

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

18.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOXX
HOTH
Founded
2017
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.9M
18.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
FOXX
HOTH
Price
$4.57
$1.21
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
2.7M
276.6K
Earning Date
11-18-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$63,030,415.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
139.29
N/A
52 Week Low
$1.71
$0.66
52 Week High
$11.00
$3.80

Technical Indicators

Market Signals
Indicator
FOXX
HOTH
Relative Strength Index (RSI) 59.39 44.22
Support Level $1.71 $1.14
Resistance Level $6.90 $1.24
Average True Range (ATR) 0.89 0.08
MACD 0.28 0.01
Stochastic Oscillator 54.12 65.29

Price Performance

Historical Comparison
FOXX
HOTH

About FOXX Foxx Development Holdings Inc. Common Stock

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

Share on Social Networks: